First Light Acquisition Group, LLC's Form 4 filing
Calidi Biotherapeutics, Inc. (CLDI) · filed Sep 14, 2022
- Accession no.
- 0000899243-22-031083
- Filed
- Sep 14, 2022, 8:12 PM ET
- Trade date
- Sep 12-13, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 0 non-derivative transactions and 2 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| First Light Acquisition Group, LLCCIK 0001855489 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2022 | Class A Common Stock, par value $0.0001 per share | SSaleDisposed | −450,000 | $1.00 | −$450,000 | 2,874,677 | Indirect | |
| Sep 13, 2022 | Class A Common Stock, par value $0.0001 per share | SSaleDisposed | −400,000 | $0.10 | −$40,000 | 2,575,803 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.